ライフサイエンスコーパス: orchiectomy

1 one agonist or antagonist or after bilateral orchiectomy.

2 pseudotumor may eventuate in an unnecessary orchiectomy.

3 ot significantly different between GnRHa and orchiectomy.

4 cally relevant adverse effects compared with orchiectomy.

5 GnRH) agonists, and 3,747 underwent surgical orchiectomy.

6 s were diagnosed within the first year after orchiectomy.

7 dergoing CT surveillance in the decade after orchiectomy.

8 y and, in case of testicular involvement, by orchiectomy.

9 ported results as a hazard ratio relative to orchiectomy.

10 an LHRH agonist was equivalent to that after orchiectomy.

11 (95% CI, 1.00-1.46) after orchiectomy vs no orchiectomy.

12 plus bilateral orchiectomy with placebo plus orchiectomy.

13 rly-stage testicular seminoma after inguinal orchiectomy.

14 Testes were weighed following bilateral orchiectomies.

15 egun treatment (71% chemical castration, 29% orchiectomy) a median of 2 years previously.

16 The relapse rate after orchiectomy alone was 30.6% at 5 years.

17 atients with PCa (24.3%) underwent bilateral orchiectomy and 11,137 patients (75.7%) received GnRHa t

18 lack:white rate ratio was 2.45 for bilateral orchiectomy and 3.64 for amputations of all or part of t

19 es emerges as a sound alternative to radical orchiectomy and allows for preservation of spermatogenes

20 ograft mouse model after treatment with both orchiectomy and ARN-509 but not with vehicle.

21 actate dehydrogenase [LDH]) before and after orchiectomy and before chemotherapy for those with extra

22 Persistent marker elevation after orchiectomy and before retroperitoneal lymphadenectomy w

23 of the prostate to treatment with bilateral orchiectomy and either flutamide or placebo.

24 lly significant difference was noted between orchiectomy and GnRHa for diabetes and cognitive disorde

25 Five of the 6 patients were treated with orchiectomy and had durable responses (median follow-up,

26 d in rat lacrimal glands 15 to 31 days after orchiectomy and pituitary removal, and no aqueous tear d

27 LCD was associated with unilateral orchiectomy and the same risk factors as LCF; no signifi

28 sy necrotizing epididymo-orchitis (requiring orchiectomy) and then Gram-negative meningitis, despite

29 reatment (1 month before until 1 month after orchiectomy), and post-treatment periods (1 month after

30 He underwent a left radical orchiectomy, and pathology showed a 1.5-cm mixed germ ce

31 treatment, starting with a radical inguinal orchiectomy, are important to optimize outcomes.

32 Importantly, orchiectomy, but not ovariectomy, abolishes the sex diff

33 an potentially be useful in deciding whether orchiectomy can be replaced with follow-up or less invas

34 Orchiectomy can result in durable remissions for these p

35 The addition of flutamide to bilateral orchiectomy does not result in a clinically meaningful i

36 ogens, combined androgen blockade, bilateral orchiectomy, estrogens, and combination of the above.

37 erved within the first 2 years/3 years after orchiectomy for CSI nonseminoma (90%)/CSI seminoma (92%)

38 majority of relapses occur within 2 years of orchiectomy for CSI nonseminoma and within 3 years for C

39 Eligible participants had undergone orchiectomy for stage I seminoma with no adjuvant therap

40 med in 171 patients who previously underwent orchiectomy for testicular neoplasm.

41 there were higher CV ischemic events in the orchiectomy group than in the GnRHa group (hazard ratio,

42 ption of SC demyelination and lesion scores, orchiectomy had no effect on histopathological QT.

43 analyses, patients who received a bilateral orchiectomy had significantly lower risks of experiencin

44 ts, compared with patients treated with only orchiectomy, had an increased risk for a second cancer (

45 lstilbestrol (DES), leuprolide, or bilateral orchiectomy has been reported to be equivalent.

46 for erectile dysfunction, incontinence, and orchiectomy have been successful, widely used and of low

47 I testis tumor who are on surveillance after orchiectomy, have a suitable partner, and attempt impreg

48 HRH agonists to be essentially equivalent to orchiectomy (hazard ratio, 1.262 [95% CI, 0.915 to 1.386

49 isited due to the significant association of orchiectomy histology with pcRPLND pathology and the ben

50 ble (non-teratoma) germ cell tumor (GCT) pre-orchiectomy; however, its ability to detect occult disea

51 ncident CVD, 1.21; 95% CI, 1.18 to 1.25; and orchiectomy: HR, 1.16; 95% CI, 1.08 to 1.25).

52 nagement strategies that may follow inguinal orchiectomy in clinical stage I seminoma.

53 dent cases of testicular cancer treated with orchiectomy in Ontario, Canada, were identified using th

54 es did not affect choice in females, whereas orchiectomies increased impulsive choice in males.

55 cell proliferation in tumors and blocked the orchiectomy-induced expression of histone acetylases, p3

56 One treatment strategy after orchiectomy is adjuvant chemotherapy.

57 Nonetheless, orchiectomy is associated with higher rates of CV ischem

58 arkers to screen for GCTs, to decide whether orchiectomy is indicated, or to select treatment for pat

59 The absence of testosterone after orchiectomy led to increased arthritis, lung disease, an

60 derson Cancer Center (Houston, TX) with post-orchiectomy megavoltage XRT between 1951 and 1999, 453 n

61 f serum testosterone concentration following orchiectomy (Ocx) and testosterone injections.

62 95% CI, 1.24 to 2.06), and an HR of CVD with orchiectomy of 1.79 (95% CI, 1.16 to 2.76) versus the co

63 The patients were treated with bilateral orchiectomy or GnRHa therapy.

64 Gonadal androgen suppression (castration via orchiectomy or gonadotropin-releasing hormone analogues)

65 Bilateral orchiectomy or luteinizing hormone releasing hormone ago

66 Bilateral orchiectomy or luteinizing hormone-releasing hormone ago

67 n therapy use was defined as prior bilateral orchiectomy or pharmacologic ADT administered within the

68 d (block size of four), by whether bilateral orchiectomy or receipt of luteinising hormone-releasing

69 before and 7 d after treatment with ARN-509, orchiectomy, or control vehicle.

70 gonadotropin-releasing hormone, or bilateral orchiectomy, or to be followed until disease progression

71 d had primary testicular tumor specimen from orchiectomy (ORCH) were included.

72 -making task, followed by ovariectomy (OVX), orchiectomy (ORX), or sham surgery.

73 ients reported more breast swelling than did orchiectomy patients (24.9% v 9.7%, P <.01).

74 lth as fair or poor more frequently than did orchiectomy patients (35.4% v 28.1%, P =.01) and also we

75 because of cancer or its treatment than did orchiectomy patients.

76 reatment (2 years prior until 1 month before orchiectomy), peritreatment (1 month before until 1 mont

77 Patients undergoing bilateral orchiectomy, receiving gonadotropin-releasing hormone an

78 Here, we show that orchiectomy reciprocally increases CSD susceptibility in

79 eline PSA, Gleason sum, history of bilateral orchiectomies, regional lymph node metastases at diagnos

80 Orchiectomy resulted in modestly significant increases i

81 interval (CI) 1.35-2.56] and teratoma in the orchiectomy specimen (OR 3.09, 95% CI 2.27-4.23) were ea

82 r size > 4 cm or rete testis invasion of the orchiectomy specimen did not affect recurrence.

83 mary landing zones and MIB-1 staining of the orchiectomy specimen, 41 patients were classified as low

84 Lymphovascular invasion in the orchiectomy specimen, a high-risk pathologic feature, wa

85 Using volume of embryonal carcinoma in the orchiectomy specimen, lymph node diameters in the primar

86 thology Registry, histologic slides from the orchiectomy specimens were retrieved and reviewed blinde

87 al mass size, and lymphovascular invasion at orchiectomy, the presence of yolk sac tumor [odds ratio

88 nagement of ETT, which varies from immediate orchiectomy to conservative treatment resulting in testi

89 be considered for reoperative orchiopexy or orchiectomy to prevent testicular cancer.

90 The median time from orchiectomy to relapse was 19 months (95% CI, 17 to 23 m

91 ), and post-treatment periods (1 month after orchiectomy until end of follow-up).

92 Conclusion Compared with bilateral orchiectomy, use of GnRHa does not increase the risk of

93 vs no ADT and 1.21 (95% CI, 1.00-1.46) after orchiectomy vs no orchiectomy.

94 sess whether treatment with GnRH agonists or orchiectomy was associated with diabetes, coronary heart

95 , the increased risk for GnRHa compared with orchiectomy was noted for fractures (HR, 1.80), peripher

96 Orchiectomy was often performed in the past; however, th

97 When orchiectomy was performed 10 days after tumor implantati

98 oma entirely replaced the normal parenchyma, orchiectomy was performed.

99 osis of metastatic PCa treated with GnRHa or orchiectomy were identified between years 1995 and 2009,

100 Men treated with orchiectomy were more likely to develop diabetes (adjust

101 Paired measurements before and after orchiectomy were performed in 424 patients; 118 with sys

102 He underwent left inguinal orchiectomy, which disclosed testicular carcinoma compos

103 His previous treatment included orchiectomy, which revealed a 5-cm tumor that was 95% yo

104 trial, we compared flutamide plus bilateral orchiectomy with placebo plus orchiectomy.

105 and ligature-induced bone loss (n = 10); (3) orchiectomy without ligature (Ocx; n = 10); (4) Ocx and

106 term survivors of seminoma treated with post-orchiectomy XRT are at significant excess risk of death